Long-term outcomes of total body irradiation plus cyclophosphamide versus busulfan plus cyclophosphamide as conditioning regimen for acute lymphoblastic leukemia: a comparative study.
| Autor: | Sakellari, Ioanna, Gavriilaki, Eleni, Papathanasiou, Maria, Mallouri, Despina, Batsis, Ioannis, Bousiou, Zoi, Bouziana, Stella, Constantinou, Varnavas, Douka, Vassiliki, Apostolou, Chrysa, Iskas, Michalis, Lalayanni, Chrysavgi, Athanasiadou, Anastasia, Sotiropoulos, Damianos, Yannaki, Evangelia, Gianouzakos, Vasilis, Anagnostopoulos, Achilles, Chatziioannou, Konstantinos |
|---|---|
| Předmět: |
TOTAL body irradiation
HEMATOPOIETIC stem cell transplantation LYMPHOBLASTIC leukemia PATIENTS THROMBOTIC thrombocytopenic purpura MYCOSES LYMPHOBLASTIC leukemia treatment BUSULFAN AGE distribution COMPARATIVE studies GRAFT versus host disease IMMUNOSUPPRESSION INFECTION LONGITUDINAL method RESEARCH methodology MEDICAL cooperation PROGNOSIS RADIOTHERAPY RESEARCH THROMBOCYTOPENIA EVALUATION research TREATMENT effectiveness DISEASE remission RETROSPECTIVE studies CYCLOPHOSPHAMIDE KAPLAN-Meier estimator THERAPEUTICS |
| Zdroj: | Annals of Hematology; Oct2018, Vol. 97 Issue 10, p1987-1994, 8p |
| Abstrakt: | The role of total body irradiation (TBI) in allogeneic hematopoietic stem cell transplantation (HCT) for adult acute lymphoblastic leukemia (ALL) remains controversial. Therefore, we investigated long-term treatment outcomes of transplanted ALL patients aiming to identify prognostic factors and the impact of conditioning. We enrolled consecutive ALL patients transplanted from 1990 to 2016, following TBI- or busulfan (Bu)-based conditioning regimen. We studied 151 ALL patients transplanted in first complete remission (CR) (60), other CR (33), or relapsed/refractory disease (58) from sibling (87), and HLA-matched (42) or mismatched (17) unrelated and alternative donors (5). High-dose fractionated TBI-based conditioning was administered in 84. No differences were observed in baseline characteristics, except for disease stage at transplant, donor type, and graft source. With a follow-up of 19.0 (0.5-170.5) in TBI and 14.5 (1.2-319.1) months in non-TBI patients, there was no difference in acute (grades II-IV) or chronic GVHD, thrombotic microangiopathy, and bacterial or fungal infections. Only viral infections were significantly increased in the non-TBI group. There was no significant difference in the cumulative incidence (CI) of treatment-related or relapse mortality and disease-free or overall survival (OS). In the multivariate analysis, unfavorable pre-transplant predictors of OS were age (p = 0.024), advanced disease stage (p = 0.007), and female-to-male donor (p = 0.006). Interestingly, TBI patients younger than 40 years had significantly higher OS (55.1%, p = 0.023) and DFS (48.6%, p = 0.020). In conclusion, high-dose TBI is feasible in younger patients providing better survival. The choice between TBI- or Bu-conditioning regimens remains challenging. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink